Results 111 to 120 of about 39,275 (210)

Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health. [PDF]

Urol Case Rep
Tariq A, Garza Gangemi A, Herrera Caceres J.   +2 more
europepmc   +1 more source

Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. [PDF]

Hum Reprod Open
Hviid KVR, Banasik K, Mortensen LH, Madsbad S, Strandberg-Larsen K, Geiker NRW, Westergaard D, Nielsen HS.   +7 more
europepmc   +1 more source

GLP-1 receptor agonist use in patients with psoriasis or hidradenitis suppurativa. [PDF]

JAAD Int
Granovsky R, Bai A, Ponyatyshyn I, Gellatly ZS, Narang J, Cobos G.   +5 more
europepmc   +1 more source

When drugs meet disease: disentangling diabetes, obesity, and periconceptional GLP-1 receptor agonist safety. [PDF]

Hum Reprod Open
Zhu Y, Hedderson MM.
europepmc   +1 more source

The Welander TIA1 mutation dedifferentiates insulin-producing cells: Reversal by a GLP-1 receptor agonist. [PDF]

J Biol Chem
Zhao T, Cen J, Wang X, Yang M, Lau J, Tengholm A, Sjöholm Å, Welsh N.   +7 more
europepmc   +1 more source

Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report. [PDF]

Oxf Med Case Reports
Baldera-Rodriguez N, Simo-Campillo N, Sanrregre-Oven P, Lopez EC, Romano R, Goicochea AB.   +5 more
europepmc   +1 more source

Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. [PDF]

Diabetes Obes Metab
Johnson H, Clift AK, Reisel D, Huang DR.
europepmc   +1 more source

Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy. [PDF]

Am J Prev Cardiol
Bal HS, Nayak A, Pampana A, Malay S, Upadhyaya A, Vekariya N, Arora G, Arora P.   +7 more
europepmc   +1 more source

GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies. [PDF]

Diabetes Metab Syndr Obes
Alourfi NM, Alorfi NM.
europepmc   +1 more source

National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss. [PDF]

J Med Toxicol
Miller J, Miller R, Varney SM, Han D.
europepmc   +1 more source